Overview of President Trump’s Executive Actions on Global Health

Published: Mar 31, 2026

Note: Originally published on Jan. 28, 2025, this resource is updated as needed, most recently on March 31, 2026, to reflect additional developments. 

Starting on the first day of his second term, President Trump began to issue numerous executive actions, several of which directly address or affect U.S. global health efforts.* This guide provides an overview of these actions, in the order in which they were issued. The “date issued” is date the action was first taken; subsequent actions are listed under “What Happens/Implications.” See an accompanying timeline of events specific to the foreign aid review and USAID dissolution.

President Trump’s Executive Actions on Global Health

Initial Rescissions Of Harmful Executive Orders And Actions, January 20, 2025
PURPOSE: Initial rescissions of Executive Orders and Actions issued by President Biden.

Among these orders are several that addressed the COVID-19 pandemic and global health security, such as Executive Order 13987 (Organizing and Mobilizing the United States Government To Provide a Unified and Effective Response To Combat COVID-19 and To Provide United States Leadership on Global Health and Security),  which among other things established the National Security Council Directorate on Global Health Security and Biodefense and a Senior Director position to oversee it.
What Happens Next/Implications: Given that most of the provisions in the COVID-19 and Global Health Security actions issued by President Biden are no longer current or relevant, the rescissions of these actions are likely to have minimal effect on government policies. One exception may be the elimination of the Directorate of Global Health Security and Biodefense and its Senior Director at the National Security Council, which were responsible for interagency coordination on global health security matters during the Biden Administration. The elimination of this office echoes a similar move made during the first Trump Administration to eliminate an NSC Directorate for Global Health Security, and raises questions about who and which offices at NSC (and across the government) will fill this coordination role in the new Administration. More rescissions of other Biden administration Executive Actions may be issued at a later date.
Withdrawing The United States From The World Health Organization, January 20, 2025
PURPOSE: To withdraw from the World Health Organization (WHO).
“The United States noticed its withdrawal from the World Health Organization (WHO) in 2020 due to the organization’s mishandling of the COVID-19 pandemic that arose out of Wuhan, China, and other global health crises, its failure to adopt urgently needed reforms, and its inability to demonstrate independence from the inappropriate political influence of WHO member states.  In addition, the WHO continues to demand unfairly onerous payments from the United States, far out of proportion with other countries’ assessed payments. China, with a population of 1.4 billion, has 300 percent of the population of the United States, yet contributes nearly 90 percent less to the WHO.”

ACTIONS: The United States intends to withdraw from the WHO. 
The Presidential Letter to the Secretary-General of the United Nations signed on January 20, 2021, that retracted the United States’ July 6, 2020, notification of withdrawal is revoked.
Executive Order 13987 (Organizing and Mobilizing the United States Government to Provide a Unified and Effective Response to Combat COVID–19 and To Provide United States Leadership on Global Health and Security), which, among other things, called for “engaging with and strengthening the World Health Organization” is revoked.
Assistant to the President for National Security Affairs shall establish directorates and coordinating mechanisms within the National Security Council apparatus as necessary and appropriate to safeguard public health and fortify biosecurity.
The Secretary of State and Director of the Office of Management and Budget shall take actions to pause future transfer of any U.S. funds, support, or resources to WHO; recall and reassign U.S. government personnel or contractors working in any capacity with WHO; and identify credible and transparent U.S. and international partners to assume necessary activities previously undertaken by WHO.
The Director of the White House Office of Pandemic Preparedness and Response Policy shall review, rescind, and replace the 2024 U.S. Global Health Security Strategy.
The Secretary of State shall immediately inform the Secretary-General of the United Nations, any other applicable depositary, and the leadership of the WHO of the withdrawal.
While the withdrawal is in progress, Secretary of State will cease negotiations on the WHO Pandemic Agreement and the amendments to the International Health Regulations, and states that “actions taken to effectuate such agreement and amendments will have no binding force on the United States.”
What Happens Next/Implications: President Trump initiated a process to withdraw from the WHO during his first term in office, a process that takes a year to finalize, and halted funding. This time period was not met when President Biden took office and he reversed this decision and restored funding. Now, after issuance of a formal letter of withdrawal United Nations and WHO, the process will be initiated once again. Such a letter has been issued, indicating that membership will end as of January 22, 2026.Per the Executive Order, U.S. government representatives may not work with WHO. While U.S. representatives attended the Executive Board meeting in February (the U.S. previously held a seat on the Executive Board), no representatives attended the World Health Assembly in May, where world leaders adopted the Pandemic Agreement. On May 30, the White House released details on the President’s Budget Request for FY 2026, requesting eliminated funding for WHO. Further, on June 3, the administration asked Congress to rescind funds previously appropriated for fiscal years 2024 and 2025, including contributions to WHO. However, for both the FY 2026 appropriations and FY2024-25 rescissions, Congress will determine the final funding levels. As the largest donor to WHO providing approximately 16%-18% of the organization’s revenue, the absence of U.S. funding will have an impact WHO’s operations, as will the loss of U.S. technical expertise. See: KFF Fact Sheet and Quick Take

Update: The formal withdrawal of the U.S. government from the WHO became effective on January 22, 2026.
Reevaluating And Realigning United States Foreign Aid, January 20, 2025
PURPOSE: To pause funding and review all U.S. foreign assistance to assess alignment with American values.

The U.S. “foreign aid industry and bureaucracy are not aligned with American interests and in many cases antithetical to American values. They serve to destabilize world peace by promoting ideas in foreign countries that are directly inverse to harmonious and stable relations internal to and among countries.”

“It is the policy of United States that no further United States foreign assistance shall be disbursed in a manner that is not fully aligned with the foreign policy of the President of the United States.”

Calls for:

90-day pause in U.S. foreign development assistance (new obligations or disbursements) to assess programmatic efficiencies and consistency with U.S. foreign policy.
Review of U.S. foreign assistance programs by the responsible department and agency heads under guidelines provided by the Secretary of State, in consultation with the Director of OMB.
Responsible department and agency heads, in consultation with the Director of OMB, will make determinations within 90 days of this order on whether to continue, modify, or cease each foreign assistance program based upon the review recommendations, with the concurrence of the Secretary of State.
New obligations and disbursements may resume for a program prior to the end of the 90-day period if a review is conducted, and the Secretary of State or his designeein consultation with the Director of OMB, decide to continue the program in the same or modified form.  Additionally, any other new foreign assistance programs and obligations must be approved by the Secretary of State or his designee, in consultation with the Director of OMB.
The Secretary of State may waive the pause for specific programs.
What Happens Next/Implications: Almost all global health programs are funded through foreign aid appropriations and are therefore subject to this order. The order temporarily freezes any new U.S. government spending (obligations or disbursements) through these programs, which could interrupt implementation of programs for which funds have not yet been obligated. It also calls for a 90-day review of all foreign aid programs. Key developments are as follows:
On January 24, 2025, A Notice on Implementation of the Executive Order was issued by USAID which, among other things, calls for stop-work orders to be issued for all existing foreign assistance awards (not just new obligations and disbursements). It notes that waivers have been granted for: foreign military financing for Israel and Egypt and emergency food assistance (and related expenses) and, on a temporary basis, salaries and related administrative expenses, including travel, for U.S. direct hire employees, personal services contractors, and locally employed staff. The stop-work order on existing awards halted U.S. global health (and other foreign assistance) programs that were already underway, placing key programs at risk of not being able to provide critical services, and affecting access for individuals on the ground, unless a waiver was received.
On January 28, the Secretary of State  issued a blanket waiver for life-saving humanitarian assistance programs, which also lays out a process for requesting additional waivers (more information is here). This guidance also states that the waiver does not apply to “activities that involve abortions, family planning, conferences, administrative costs [unless associated with waived activities], gender or DEI ideology programs, transgender surgeries, or other non-life saving assistance.”
On February 1, PEPFAR, the global HIV/AIDS program, was granted a limited waiver enabling it to resume or continue “urgent life-saving HIV treatment  services”, defined as a set of care and treatment services and prevention of mother-to-child transmission services.
On February 4, some additional services for other global health programs  – tuberculosis; malaria; acute risks of maternal and child mortality, including severe acute malnutrition; and other life-threatening diseases and health conditions – deemed to be “lifesaving” were also granted a limited waiver to allow them to resume or continue.
On February 6, a lawsuit was filed by Democracy Forward and Public Citizen Litigation Group, on behalf of the American Foreign Service Association and American Federation of Government Employees, challenging the foreign aid funding freeze, the plan to put most staff on leave, and the fact that staff had already been placed on leave; on February 7, they filed a temporary restraining order (TRO). That same day, a temporary restraining order was issued by the U.S. District Court in the District of Columbia preventing the government from placing additional staff on leave or evacuating staff back to the U.S., and requiring reinstatement of all staff already placed on leave, until February 14. The court did not grant a TRO on the funding freeze, on the grounds that the plaintiffs in this case did not demonstrate that the freeze caused them irreparable harm. On February 13, the court extended the TRO through February 21 (further actions are described below, as this case was combined with another for purposes of the court’s consideration).
On February 10, a lawsuit was filed in the U.S. District Court for the District of Columbia on behalf of two U.S. organizations seeking emergency relief from the freeze on funding for foreign assistance (AVAC v. United States Department of State).
On February 11, a lawsuit was filed in the U.S. District Court for the District of Columbia on behalf of several U.S. organizations challenging the executive order and subsequent actions freezing foreign aid and dissolving USAID, and asking the court to temporarily restrain and preliminarily and permanently enjoin Defendants from implementing these actions (Global Health Council v. Trump).
On February 13, the court, in a ruling pertaining to the February 10 and February 11 lawsuits brought by numerous U.S. organizations, issued a TRO preventing the Trump administration from “suspending, pausing, or otherwise preventing the obligation or disbursement of appropriated foreign-assistance funds in connection with any contracts, grants, cooperative agreements, loans, or other federal foreign assistance award that was in existence as of January 19, 2025; or issuing, implementing, enforcing”, or “otherwise giving effect to terminations, suspensions, or stop-work orders in connection with any contracts, grants, cooperative agreements, loans, or other federal foreign assistance award that was in existence as of January 19, 2025.”
On February 14, the parties filed a joint status report proposing an expedited preliminary injunction briefing schedule.
On February 18, the government filed a required status report stating that, despite the TRO, it had the authority to cancel contracts and suspend grant awards.
This was followed by a February 19 request by the February 10 plaintiffs (AVAC v. Department of State) for an emergency motion to enforce the TRO and to hold the defendants in civil contempt.
The defendants filed a required response on February 20, stating that they have not violated the TRO and should not be held in contempt, which was again opposed by the plaintiffs. Also on February 20, the February 11 plaintiffs (Global Health Council v. Trump) filed a response to the defendant’s status report with a motion to enforce the TRO.  The court reaffirmed the TRO on February 20 (but did not hold the defendants in contempt), stating it was prepared to hold a hearing on the preliminary injunction motions in both cases by March 4, 2025 and that the TRO would be in place through March 10, 2025, or the date the Court resolves the preliminary injunction motions, whichever is sooner.
The plaintiffs filed an emergency order to enforce the TRO on February 24, due to continued lack of payment, and the court issued a motion to enforce on February 25. The government appealed, (asking for a stay pending appeal) but this was denied by the court. The government then appealed to the Supreme Court and was granted a stay until February 28 while the case was considered.
On March 5, the Supreme Court denied the government’s request to vacate the federal district court’s TRO, sending the order back to the district court to clarify the government’s obligations for ensuring compliance with the TRO.
On March 6, the federal district court judge ordered the government to release all payments that were due to plaintiffs as of February 13, by Monday, March 10 at 6pm, and on March 10, the federal district court judge preliminarily enjoined the government from taking certain actions related to the foreign aid freeze.
On March 10, Secretary Rubio announced that a six-week review had been completed and that 83% of programs at USAID (5,200 contracts) had been cancelled. That same day, the court  preliminarily enjoined the government from enforcing actions taken to implement the foreign aid freeze (requiring it to reverse any terminations, suspensions, and stop-work orders and to pay for any work completed by February 13). The court stated that the government was “enjoined from unlawfully impounding congressionally appropriated foreign aid funds and shall make available for obligation the full amount of funds that Congress appropriated for foreign assistance programs in the Further Consolidated Appropriations Act of 2024.”
On April 1, the government filed an appeal with the U.S. Court of Appeals for the District of Columbia challenging the preliminary injunction issued on March 10.
On April 17, the administration extended the foreign aid review for another 30 days from the original deadline of April 20, 2025.
On May 2 and May 30, the White House released information on its budget request for FY 2026, proposing significant decreases, and in some cases eliminations, of funding for global health activities. However, Congress will determine the final funding levels.
On June 3, the administration asked Congress to rescind previously appropriated funds for fiscal years 2024 and 2025, including $8.3 billion in foreign assistance, of which at least $1.2 billion was designated for global health. However, Congress will need to approve any potential rescissions.
• On August 13, the U.S. District Court of Appeals for the District of Columbia Circuit partially vacated the March 10 preliminary injunction in the cases GHC v. Trump and AVAC v. State Department which required the government to make congressionally appropriated foreign assistance funds available for obligation. The appeals court ruled that the plaintiffs did not have the authority to challenge the President’s impoundment of funds. Instead, the court ruled that challenges of impoundment should be brought forward by the Comptroller General.
• On August 28, the U.S. District Court of Appeals for the District of Columbia Circuit amended its opinion, clarifying that while plaintiffs did not have the authority to challenge impoundment of foreign assistance funds through the Impoundment Control Act, they could seek relief through the Administrative Procedures Act. Following this amended opinion, plaintiffs in GHC v. Trump and AVAC v. State Department cases motioned for a preliminary injunction in the U.S. district court on September 1. On September 3, the U.S. district court granted the preliminary injunction, ordering defendants to obligate expiring foreign assistance funds before the end of the fiscal year on September 30. On September 4, defendants appealed this preliminary injunction and requested a stay on the preliminary injunction pending the resolution of the appeals case, from both the district court and appeals court. These requests were both denied on September 5. On September 8, defendants requested a stay of the preliminary injunction as it pertained to funds included in the President’s proposed rescissions package from the U.S Supreme Court. On September 9, the Chief Justice of the Supreme Court granted a partial administrative stay of the preliminary injunction, and on September 26, the court granted the partial stay, allowing the administration to rescind the $4 billion that was in rescission package. Further legal proceedings in the case are currently stayed as the parties await the outcome of a separate legal case.

The 90-day review of foreign assistance was initially supposed to go through April 19, 2025, however, has been granted a 30-day extension. No formal results of the review have been announced.
America First Policy Directive To The Secretary Of State, January 20, 2025
PURPOSE: To put core American interests first in foreign policy.

The foreign policy of the United States “shall champion core American interests and always put America and American citizens first.”

“As soon as practicable, the Secretary of State shall issue guidance bringing the Department of State’s policies, programs, personnel, and operations in line with an America First foreign policy, which puts America and its interests first.”
What Happens Next/Implications: The State Department is responsible for the supervision and overall strategic direction of foreign assistance programs administered by the State Department and USAID, which includes the vast majority of global health assistance. It also directly oversees PEPFAR, the global HIV/AIDS program, and many aspects of global health diplomacy for the U.S. Priorities and approaches for these and other global health programs are likely to be shaped by how the White House and State Department leadership define “America First” foreign policy and American interests, and how that definition is implemented in practice.

Update: On September 18, the State Department released the America First Global Health Strategy, its new vision for U.S. global health engagement. The strategy is built around three pillars — “making America safer, stronger, and more prosperous” — and prioritizes funding for direct service support, such as commodities and health workers, includes plans for country co-investment, and seeks to transition program management operations from U.S. leadership to country ownership. The State Department is entering into multi-year bilateral agreements with recipient countries and implementation of these new agreements will begin sometime in 2026.
Defending Women From Gender Ideology Extremism And Restoring Biological Truth To The Federal Government, January 20, 2025
PURPOSE: To define sex as an immutable binary biological classification and remove recognition of the concept of gender identity.

• The order states that “It is the policy of the United States to recognize two sexes, male and female” and directs the Executive Branch to “enforce all sex-protective laws to promote this reality”. Elements of the order that may affect global health programs are as follows:
Defines sex as “an individual’s immutable biological classification as either male or female”.  States that “sex” is not a synonym for and does not include the concept of “gender identity” and that gender identity “does not provide a meaningful basis for identification and cannot be recognized as a replacement for sex.”
Directs the Secretary of Health and Human Services to provide the U.S. Government, external partners, and the public clear guidance expanding on the sex-based definitions set forth in the order within 30 days.
Directs each agency and all Federal employees to “enforce laws governing sex-based rights, protections, opportunities, and accommodations to protect men and women as biologically distinct sexes, including when interpreting or applying statutes, regulations, or guidance and in all other official agency business, documents, and communications.
Directs each agency and all Federal employees, when administering or enforcing sex-based distinctions, to use the term “sex” and not “gender” in all applicable Federal policies and documents.
Directs agencies to remove all statements, policies, regulations, forms, communications, or other internal and external messages “that promote or otherwise inculcate gender ideology”, and shall cease issuing such statements, policies, regulations, forms, communications or other messages. Directs agencies to take all necessary steps, as permitted by law, to end the Federal funding of gender ideology.
Requires that Federal funds shall not be used to promote gender ideology and directs agencies to ensure grant funds do not promote gender ideology.
Rescinds multiple executive orders issued by President Biden, including: “Preventing and Combating Discrimination on the Basis of Gender Identity or Sexual Orientation” (13988) and “Advancing Equality for Lesbian, Gay, Bisexual, Transgender, Queer, and Intersex Individuals” (14075).
What Happens Next/Implications: This order is broad, directed to all federal agencies and programs. Because PEPFAR, and some other U.S. global health programs, serve people who are members of the LGBTQ community, guidance and implementation could affect the ability of these programs to reach individuals and organizations and provide them with services. In addition, the order will likely result in the removal of existing protections based on sexual orientation and gender identity, which had been provided in agency guidance for global health and development programs. Implementation guidance has been issued and all federal agencies must comply.

Update: On January 27, 2026, citing this order (among others) the Trump administration released details of the “Promoting Human Flourishing in Foreign Assistance (PHFFA)” policy which significantly expands the Mexico City Policy (see below) to also prohibit the promotion of “gender ideology” and to apply to significantly more funding and organizations.
Memorandum For The Secretary Of State, The Secretary Of Defense, The Secretary Of Health And Human Services, The Administrator Of The United States Agency For International Development, January 24, 2025
PURPOSE: To reinstate Mexico City Policy and direct review of programs per the Kemp-Kasten Amendment.

• Revokes President Biden’s Presidential Memorandum of January 28, 2021 for the Secretary of State, the Secretary of Defense, the Secretary of Health and Human Services, and the Administrator of the United States Agency for International Development (Protecting Women’s Health at Home and Abroad).
Reinstates President Trump’s Presidential Memorandum of January 23, 2017 for the Secretary of State, the Secretary of Health and Human Services, and the Administrator of the United States Agency for International Development (The Mexico City Policy).
Directs the Secretary of State, in coordination with the Secretary of Health and Human Services, to the extent allowable by law, to implement a plan to extend the requirements of the reinstated Memorandum to global health assistance furnished by all departments or agencies.
Directs the Secretary of State to take all necessary actions, to the extent permitted by law, to ensure that U.S. taxpayer dollars do not fund organizations or programs that support or participate in the management of a program of coercive abortion or involuntary sterilization.
What Happens Next/Implications: The Mexico City Policy is a U.S. government policy that – when in effect – has required foreign NGOs to certify that they will not “perform or actively promote abortion as a method of family planning” using funds from any source (including non-U.S. funds) as a condition of receiving U.S. global family planning assistance and, when in place under the Trump administration, most other U.S. global health assistance. First announced in 1984 by the Reagan administration, the policy has been rescinded and reinstated by subsequent administrations along party lines since, and expanded over time, including a significant expansion during the first Trump administration; it was widely expected that the President Trump would reinstate it in his second term and expand it further. The memorandum calls for the implementation of a plan to extend the requirements to global health assistance furnished by all departments or agencies; until the plan is ready, the scope of the new memorandum is unknown.

The memorandum also directs the Secretary of State to review programs under the Kemp-Kasten amendment, a provision of U.S. law that states that no U.S. funds may be made available to “any organization or program which, as determined by the [p]resident of the United States, supports or participates in the management of a program of coercive abortion or involuntary sterilization.” It has been used in the past to prevent funding from going to UNFPA. See: KFF Mexico City Policy explainer and related resources and Kemp-Kasten explainer.

Update: On January 7, 2026, the Trump administration announced that it had formally withdrawn from membership and participation in UNFPA, also citing the Executive Order on “Withdrawing the United States from and Ending Funding to Certain United Nations Organizations and Reviewing United States Support to All International Organizations.”

Update: Three interim final rules expanding and implementing the Mexico City Policy, now called the Promoting Human Flourishing in Foreign Assistance (PHFFA) Policy, were issued on January 27, 2026:
Protecting Life in Foreign Assistance
Combating Gender Ideology in Foreign Assistance
Combating Discriminatory Equity Ideology in Foreign Assistance Rules
This latest expansion now includes most non-military foreign assistance and applies to U.S. NGOs, international organizations, and foreign governments, as well as foreign NGOs. In addition to abortion, it also now prohibits the promotion of “discriminatory equity ideology” and “gender ideology.”

Renewed Membership in the Geneva Consensus Declaration on Promoting Women’s Health and Strengthening the Family, January 24, 2025
PURPOSE: To rejoin the Geneva Consensus Declaration.

The United States informed signatories of the Geneva Consensus Declaration of its intent to rejoin immediately. Established in 2020, the declaration, led by the United States, has the following objectives: “to secure meaningful health and development gains for women; to protect life at all stages; to defend the family as the fundamental unit of society; and to work together across the UN system to realize these values.”
What Happens Next/Implications: The Geneva Consensus Declaration, initially crafted and signed by the U.S. – along with 31 other countries at the time – was meant to enshrine certain values and principles related to women’s health and family, including a rejection of the “international right to abortion.”  The Biden administration withdrew from the Consensus in 2021.
Review of and Changes to USAID, January 27, 2025
Reorganization of the Department of State, April 22, 2025
PURPOSE: To review and potentially reorganize USAID “to maximize efficiency and align operations with the national interest,” which may include the suspension or elimination of programs, projects, or activities; closing or suspending missions or posts; closing, reorganizing, downsizing, or renaming establishments, organizations, bureaus, centers, or offices; reducing the size of the workforce at such entities; and contracting out or privatizing functions or activities performed by federal employees.What Happens Next/Implications: Related to but separate from the Executive Order on reevaluating and realigning foreign aid and on the America first policy directive to the Secretary of State, the administration has made changes to and begun a review of USAID, the U.S. government’s international development agency which oversees and/or implements most U.S. global health programs (see, The U.S. Government and Global Health). Key developments are as follows:
On January 27, senior USAID career staff were placed on leave and hundreds of other staff were let go.
On February 2, the USAID website was taken down.
On February 3, the USAID building in DC was closed, which has prevented other staff from accessing it.
The President appointed Secretary of State Rubio as Acting USAID Administrator on February 3. Secretary Rubio has said that the agency has “conflicting, overlapping, and duplicative functions that it shares with the Department of State” and that its systems and processes are not “well synthesized, integrated, or coordinated, and often result in discord in the foreign policy and foreign relations of the United States.” President Trump and other administration officials have called for dissolving the agency altogether. Formal notification of the intent to review the agency was sent by Secretary Rubio to Congress on February 3.
On February 4, a notice was posted on the USAID website stating that on February 7, all USAID direct hire personnel would be placed on administrative leave globally, with the exception of “designated personnel responsible for mission­ critical functions, core leadership and specially designated programs.” The notice also said that staff posted outside the United States would need to return to the U.S. within 30 days.
On February 6, a lawsuit was filed by Democracy Forward and Public Citizen Litigation Group, on behalf of the American Foreign Service Association and American Federation of Government Employees, challenging the foreign aid funding freeze, the plan to put most staff on leave, and the fact that staff had already been placed on leave; on February 7, they filed for a temporary restraining order (TRO). That same day, a temporary restraining order was issued by the U.S. District Court in the District of Columbia preventing the government from placing additional staff on leave or evacuating staff back to the U.S., and requiring reinstatement of all staff already placed on leave, until February 14. The court did not grant a TRO on the funding freeze, on the grounds that the plaintiffs in this case did not demonstrate that the freeze caused them irreparable harm. On February 13, the court extended the TRO through February 21, at which time, the court determined that further preliminary injunctive relief was not warranted and the TRO was ended, allowing the government to dismiss USAID staff.
On February 11, a lawsuit was filed in the U.S. District Court for the District of Columbia on behalf of several U.S. organizations challenging the executive order pausing foreign aid, and subsequent actions freezing foreign aid and dissolving USAID, and asking the court to temporarily restrain and preliminarily and permanently enjoin Defendants from implementing these actions. In a February 13 ruling, a federal court issued a TRO preventing the Trump administration from freezing foreign aid assistance but stated that the proposed injunctions related to USAID were overbroad (in a separate case, the district court ended the TRO on dismissing USAID staff – see above).
On February 13, a lawsuit was filed in the U.S. District Court for the District of Maryland by 26 former and current employees of USAID, suing Elon Musk and DOGE for taking actions to control and dissolve the agency. On February 18, the plaintiffs filed a motion for preliminary injunction. The defendants responded on February 24 and the plaintiffs replied on February 26. On March 18, the court granted a preliminary injunction, requiring the defendants to reverse many of the actions taken to dissolve USAID, and on March 21, the defendants filed an appeal on the preliminary injunction. On March 25, the U.S. 4th Circuit Court of Appeals granted the defendants’ motion for a temporary stay on the preliminary injunction, allowing DOGE to resume its efforts to dissolve USAID, until March 27. The following day on March 28, the court granted defendants’ motion for a stay, clearing the path for DOGE to continue its work dissolving USAID.
On February 18, a lawsuit was filed in the U.S. District Court for the District of Columbia on behalf of the Personal Services Contractor Association (representing USAID personal service contractors) challenging the suspension of foreign assistance and the actions related to USAID, including “steps to dismantle USAID, cripple its operations, or transfer its functions to the State Department without Congressional authorization”. On February 19, the plaintiffs filed a motion for a temporary restraining order. On March 6, the court denied the TRO request.
On March 28, Secretary Rubio announced that the Department of State and USAID have notified Congress on their intent to “undertake a reorganization that would involve realigning certain USAID functions to the Department by July 1, 2025, and discontinuing the remaining USAID functions that do not align with Administration priorities.” Additionally, nearly all the remaining USAID staff received notice that they would be subject to a final reduction-in-force.
On April 22, Secretary Rubio announced the Department of State’s reorganization plan and new organization chart. The plan states that it would consolidate functions and remove non-statutory programs that are “misaligned with America’s core national interests.”
On April 28, a lawsuit was filed by a group of labor unions, non-profits, and local governments challenging the administration’s moves to drastically reshape several federal agencies without congressional approval (American Federation of Government Employees v. Trump). The district court issued a TRO on May 9 and preliminary injunction on May 22 ordering the administration to pause large-scale reductions in force, program eliminations, and other actions related to federal agency restructuring. An emergency motion by the government for a stay pending appeal of the district court’s preliminary injunction was denied on May 30.
On May 2 and May 30, the White House released information on its budget request for FY 2026, noting the reorganization of USAID into the Department of State.
On May 29, the Department of State notified Congress of its reorganization plans, including absorbing USAID’s continued functions.
On June 13, the district court in American Federation of Government Employees v. Trump ruled that the actions of the Department of State, including the reorganization announcement and notification to Congress, were in violation of the preliminary injunction.
On July 8, the U.S. Supreme Court granted the government’s request for a stay of the preliminary injunction pending resolution of the appeals case in American Federation of Government Employees v. Trump, allowing the government to move forward with large-scale reductions to federal agency operations and workforces, including at the State Department.

While initially created through Executive Order in 1961 as part of the State Department, the Foreign Affairs Reform and Restructuring Act of 1998 established it as an independent agency within the executive branch. As such, the Executive branch does not have authority to dissolve it without Congress, and Congress also requires notification first as well as consultation on any proposed changes.

Update: On July 1, 2025, USAID was dissolved (with most employees being separated from the agency; any remaining personnel were separated by September 2, 2025). Remaining functions/activities were transferred to the State Department.
Withdrawing the United States From and Ending Funding to Certain United Nations Organizations and Reviewing United States Support to All International Organizations, February 4, 2025
PURPOSE: To review United States participation in all international intergovernmental organizations, conventions, and treaties and to withdraw from and end funding to certain United Nations (U.N.) organizations.

The U.S. “helped found” the U.N. “after World War II to prevent future global conflicts and promote international peace and security.  But some of [its] agencies and bodies have drifted from this mission and instead act contrary to the interests of the United States while attacking our allies and propagating anti-Semitism.”
States that the U.S. “will reevaluate our commitment to these institutions,” including three organizations that “deserve renewed scrutiny”:
a) the U.N. Human Rights Council (UNHRC; the U.S. will not participate in and withhold its contribution to the budget of the body),
b) the U.N. Educational, Scientific, and Cultural Organization (UNESCO; the U.S. will conduct a review of its membership in the body within 90 days), and
c) the U.N. Relief and Works Agency for Palestine Refugees in the Near East (UNRWA; reiterates that the U.S. will not contribute to the body).
Requires that within 180 days:
a) the Secretary of State, with the U.S. Ambassador to the U.N., conduct a review of all international intergovernmental organizations of which the U.S. is a member and provides any type of funding or other support, and all conventions and treaties to which the United States is a party, to determine which organizations, conventions, and treaties are contrary to the interests of the United States and whether such organizations, conventions, or treaties can be reformed; and
b) the Secretary of State to report the findings of the review to the President, through the National Security Advisor, and provide recommendations as to whether the U.S. should withdraw from any such organizations, conventions, or treaties.
What Happens Next/Implications: With a long history of multilateral global health engagement, the U.S. is often the largest or one of the largest donors to multilateral health efforts (i.e., multi-country, pooled support often directed through an international organization). It provided $2.4 billion in assessed or core contributions in FY 2024 – 19% of overall U.S. global health funding – as well as more funding in voluntary or non-core contributions.

The U.S. is also a signatory or party to numerous global health-related international conventions, treaties, and agreements; these include those that played a role in the global COVID-19 response (such as the International Health Regulations). It often has participated in negotiations for new international instruments, although the Trump administration indicated in a Jan. 20, 2025, Executive Order, listed above, that the U.S. would no longer engage in the Pandemic Agreement (sometimes called the “Pandemic Treaty”) negotiations.

This Executive Order will have immediate impacts via the ordered actions related to the three U.N. organizations specified, much as the impacts of the Jan. 20, 2025, Executive Order on the World Health Organization (WHO, which initiated U.S. withdrawal from membership and halted U.S. funding) are already being seen. Beyond these, additional impacts of this Executive Order will be determined by the findings and recommendations of the international organizations and conventions review, particularly if U.S. support for or membership in some international organizations is recommended to be reduced or eliminated and if it recommends the U.S. withdraw from any international agreements.

The 180 day review of all international intergovernmental organizations goes through August 3, 2025.

Update: On January 7, 2026, the Trump administration announced that it had formally withdrawn from 66 international organizations, including United Nations entities and non-UN entities.  
Memorandum For The Heads Of Executive Departments And Agencies, February 6, 2025
PURPOSE: The memorandum seeks to “stop funding Nongovernmental Organizations that undermine the national interest and administration priorities”.

The memorandum:
States: it is Administration policy “to stop funding NGOs [Nongovernmental Organizations] that undermine the national interest.”
Directs heads of executive departments and agencies to review all funding that agencies provide to NGOs and “to align future funding decisions with the interests of the United States and with the goals and priorities of my Administration, as expressed in executive action; as otherwise determined in the judgment of the heads of agencies; and on the basis of applicable authorizing statues, regulations, and terms.”
What Happens Next/Implications: This memo aligns with other Executive actions that target federal funding for global health and foreign assistance programs. Implementation of this memo could result in the Administration halting funding to global health NGOs they determine “do not align with administration priorities.” No criteria for how this determination will be made has been provided.

The majority of U.S. global health assistance is channeled through NGOs. In FY22, for example, 62% of U.S. global health funding was provided to NGOs as prime partners (45% to U.S.-based NGOs and 17% to foreign-based NGOs) and others are likely sub-recipients of U.S. assistance.* As such, this Order could have a significant impact on NGOs if it is determined that they do not align with administration policies. *Source: KFF analysis of data from www.foreignassistance.gov.
Addressing Egregious Actions of The Republic of South Africa, February 7, 2025
PURPOSE: To stop U.S. support for South Africa due to its “commission of rights violations in its country or its ‘undermining United States foreign policy, which poses national security threats to our Nation, our allies, our African partners, and our interests.”

“It is the policy of the United States that, as long as South Africa continues these unjust and immoral practices that harm our Nation:
(a)  the United States shall not provide aid or assistance to South Africa; and
(b)  the United States shall promote the resettlement of Afrikaner refugees escaping government-sponsored race-based discrimination, including racially discriminatory property confiscation.”

ACTIONS:
All executive departments and agencies, including USAID, shall, to the maximum extent allowed by law, halt foreign aid or assistance delivered or provided to South Africa, and shall promptly exercise all available authorities and discretion to halt such aid or assistance.
The head of each agency may permit the provision of any such foreign aid or assistance that, in the discretion of the relevant agency head, is necessary or appropriate.
The Secretary of State and the Secretary of Homeland Security shall take appropriate steps, consistent with law, to prioritize humanitarian relief, including admission and resettlement through the United States Refugee Admissions Program, for Afrikaners in South Africa. A plan shall be submitted to the President through the Assistant to the President and Homeland Security Advisor.
What Happens Next/Implications: South Africa receives a significant amount of global health assistance, particularly for HIV/AIDS, from the United States government. The executive order allows the heads of U.S. agencies to permit the provision of foreign aid or assistance under this order at their discretion. On February 10, the U.S. Embassy and Consulates in South Africa announced that PEPFAR would not be impacted by this Executive Order and could continue under the limited waiver already granted to the foreign aid funding freeze. No other exceptions have yet been announced.

The Government of South Africa has issued a statement in response to the Executive Order that, among other things, expresses concern “by what seems to be a campaign of misinformation and propaganda aimed at misrepresenting our great nation.”

Notes and Sources:

*There are several other Executive Actions issued by the President that instruct all government agencies on a variety of topics and as such broadly affect global health program operations but are not specific to global health. These include, for example, Executive Actions withdrawing from the Paris Agreement under the United Nations Framework Convention on Climate Change and ending DEI programs. These are not included in this resource.

Sources: White House, https://www.whitehouse.gov/presidential-actions/; State Department, www.state.gov.

How Does U.S. Life Expectancy Compare to Other Countries?

Published: Mar 31, 2026

Life expectancy at birth in the U.S. increased 0.6 years from 78.4 years in 2023 to 79.0 years in 2024, its highest-ever level. However, the average life expectancy in comparable countries was 82.7 years, about 3.7 years longer than in the U.S., reflecting a persistently wide difference in life expectancy between the U.S. and comparable countries.

This chart collection examines how life expectancy in the U.S. compares to that of other similarly large and wealthy countries in the Organisation for Economic Co-operation and Development (OECD). The countries included in the comparison are Australia, Austria, Belgium, Canada, France, Germany, Japan, Netherlands, Sweden, Switzerland, and the United Kingdom.

The analysis is available through the Peterson-KFF Health System Tracker, an information hub dedicated to monitoring and assessing the performance of the U.S. health system.

Poll Finding

Public Opinion on Prescription Drugs and Their Prices

Published: Mar 31, 2026

Editorial Note: This data note was updated on March 31, 2026, to reflect updated poll findings.

Key Takeaways

This data note summarizes KFF polling on the U.S. public’s experiences with prescription drug costs, use of GLP-1 medications, and support for policy solutions. Key takeaways include:

  • Most U.S. adults take at least one prescription drug, and many struggle or worry about affording their prescription medications. Six in ten adults say they are worried about being able to afford their prescription drug costs, a new high since KFF began asking in 2018. Four in ten say they have had to take cost-saving measures, such as skipping doses, not filling prescriptions, or taking other measures due to costs.
  • Increasing use of GLP-1 medications raises particular cost concerns. About one in five adults have ever taken a GLP-1 medication, and most users – including those with health insurance – say these drugs are difficult to afford. KFF will continue to monitor the public’s experiences with GLP-1 medications as use, regulation, and new formulations – including oral versions – continue to evolve.
  • Large majorities across party lines want the government to do more to regulate drug prices, and many support a range of policies. At least two-thirds of Democrats, independents, and Republicans say there is not enough regulation of prescription drug prices. Most support a range of policies to address costs, such as two provisions of the 2022 Inflation Reduction Act (IRA): allowing Medicare to negotiate prices and limiting how much drug companies can increase the price of drugs based on annual inflation rates.
  • The Trump administration has taken several steps to try to lower prescription drug costs in its second term, but these initiatives have limited public visibility so far. Few adults have heard much about the administration’s drug pricing deals with manufacturers or TrumpRx, the federal website that provides discount coupons for certain drugs, launched in early 2026. KFF polling from 2019 found broad support for a related approach – lowering what Medicare pays for some drugs based on amounts in other countries – suggesting the idea has public appeal even if awareness of the current initiatives and the debates around them remain low.

The Public’s Experiences with and Views of Prescription Drugs

Prescription drugs touch the lives of most people in the U.S. in some way, and the public broadly recognizes their benefits. About two-thirds (66%) of adults say they are currently taking at least one prescription drug, and three in ten (31%) say they currently take four or more prescription medications. While many adults across age groups take prescription medications, older adults are much more likely to report taking 4 or more medications.

Six in ten adults ages 65 and older report taking four or more prescription medications, compared to fewer than half of younger adults.

Bar chart showing the percent who take any number of prescription medicine, 1 prescription medicine, 2 prescription medicines, 3 prescription medicines, or 4 or more prescription medicines.

The public generally sees the benefits of these medicines. About six in ten (63%) adults believe prescription drugs developed over the past 20 years have generally made the lives of people in the U.S. better, while much smaller shares (21%) say they’ve made them worse or have not made a difference (15%).

Six in Ten Say That Prescription Drugs Developed Over the Past 20 Years Have Made the Lives of People in the U.S. Better (Stacked Bars)

Despite seeing their general benefits to society, about eight in ten adults (82%) say the cost of prescription drugs is unreasonable, and the public sees profits made by pharmaceutical companies as the largest factor contributing to these prices. More than three-quarters of adults across partisanship say profits made by pharmaceutical companies are a “major factor” in the price of prescription drugs. This is followed by more than half who say the cost of research and development is a “major factor” contributing to the price, and 45% saying the same about the cost of marketing and advertising.

Split bar chart by total and party identification, showing the percent who say each of the following is a major factor contributing to the price of prescription drugs: profits made by pharmaceutical companies, the cost of research and development, and the cost of marketing and advertising.

Struggles Affording Prescription Drugs

Many Americans face significant challenges affording their medications, including adults who take more medications or have lower incomes. KFF polling shows these challenges have grown more acute over the years. While about two-thirds (65%) of adults overall say it is “very” or “somewhat” easy to afford their prescription drug costs, affordability is a bigger issue for those who are currently taking four or more prescription medicines. Nearly four in ten (37%) of those taking four or more prescription drugs say they have difficulty affording their prescriptions, compared with one in five (18%) adults who currently take three or fewer prescription medications. Adults with an annual household income of less than $40,000 are also more likely than adults with higher incomes to report difficulty affording their prescription medications.

Bar chart showing percent who say it is difficult to afford the cost of their prescription medicine, by total, number of medications taken, age, and household income.

Overall, about six in ten adults say they are worried about being able to afford prescription drug costs for themselves or their families (59%), including about one in five (22%) who are “very worried.” Worry varies by insurance status, household income, race, and ethnicity. Substantial shares of uninsured adults under age 65 (32%), Hispanic adults (30%), Black adults (26%), and adults in households with annual incomes less than $40,000 (27%) say they are “very worried” about affording their prescription drug costs.

Among adults who take four or more prescription medications, about two-thirds (64%) report worrying about affording their medications, including about three in ten (29%) who are “very worried.” However, worry is not limited to those who take at least four medications. Most adults who take fewer prescriptions (1 to 3) worry about being able to afford their medications (56%). Even among adults who do not currently take any prescriptions themselves, a majority (57%) are “very” or “somewhat worried” about affording prescription medications, perhaps reflecting concerns about future needs or the prescription drug costs of family members.

Notably, about one in five (19%) Medicare enrollees say they are “very worried” about affording their prescription drug costs. Although older adults are more likely to take more prescription medications than younger adults, the vast majority of Medicare beneficiaries are enrolled in Medicare Part D plans, giving them prescription drug coverage that has improved with recent policies in the Inflation Reduction Act of 2022.

About one in four (24%) Medicaid enrollees under age 65 say they are “very worried” about affording their prescription drug costs. Medicaid provides comprehensive access to prescription drugs for eligible adults, with out-of-pocket costs limited to nominal amounts, which helps adults avoid cost-related prescription medication rationing or delays. However, while prescription out-of-pocket costs in Medicaid are limited, even low amounts may still be prohibitive for low-income families with Medicaid.

Majorities Are Worried About Affording Prescription Drugs for Themselves or Their Family (Stacked Bars)

Since KFF first asked about worries affording prescription drug costs in 2018, the share of adults reporting worries has increased steadily, to a new high of six in ten (59%) in 2026.

Bar chart showing the share of adults who are very or somewhat worried about being able to afford prescription drugs from August 2018 to March 2026.

About four in ten (43%) adults report that they have not taken their medication as prescribed at some point in the past year because of the cost. This includes three in ten who have taken an over-the-counter drug instead (31%), a quarter who have not filled a prescription (27%), and about one in five (19%) who have cut pills in half or skipped doses of medicine because of the cost.

The share who reports not filling a prescription, taking an over-the-counter drug instead, or cutting pills in half or skipping doses increases to about half among adults with annual household incomes less than $40,000 (52%).

About Four in Ten Adults Say, in the Past Year, They Did Not Take Their Medicine as Prescribed Due to Costs (Split Bars)

GLP-1 Use and Affordability

In recent years, KFF has been tracking the public’s use and experiences with GLP-1 medications. These medications, such as semaglutide or tirzepatide, are used for weight loss or managing chronic health conditions. As GLP-1 medications have expanded beyond their original use for treating Type 2 diabetes, their popularity, combined with their high cost and need for long-term use, poses a potential cost burden on consumers, employers, and insurers. In response, some employers have restricted or dropped coverage for weight loss in 2026. Medicare Part D currently covers GLP-1 drugs only when prescribed to treat chronic illnesses such as diabetes and sleep apnea but prohibits the coverage for weight loss alone under federal law. Under the Medicaid Drug Rebate Program (MDRP), state Medicaid programs must cover GLP-1s for conditions like diabetes, but coverage for obesity is optional under federal law.

As of March 2026, KFF Health Tracking Polls show about one in five adults have ever taken a GLP-1 medication (18%), including 12% who currently take this class of medication (an increase of 6 percentage points from May 2024).

While most GLP-1 users get their medications from a primary care doctor and have them at least partially covered by insurance, a majority, including 55% of those who have health insurance, say it is difficult to afford these drugs. KFF will continue to monitor the public's experiences with GLP-1 medications as use, regulation, and new formulations – including oral versions – continue to evolve.

Stacked bar chart showing how easy or difficult paying for GLP-1 drugs is for adults who have ever used GLP-1 drugs.

Public Support for Drug Pricing Policies

There is broad, bipartisan agreement that there should be more government regulation when it comes to prescription drug costs. The March 2026 KFF Health Tracking Poll finds about seven in ten adults (72%) say there is “not as much regulation as there should be” when it comes to limiting the price of prescription drugs, including at least two-thirds of Democrats (77%), Republicans (68%), and independents (72%).

Notably, larger shares of adults now say there is not enough regulation than five years ago, though KFF has found bipartisan agreement on this attitude since 2015.

Split bar chart by total and party identification showing percent of adults who say that there is not as much regulation as there should be when it comes to making sure prescription drugs are safe for people to use and limiting the price of prescription drugs.

For decades, lawmakers have debated and passed drug pricing legislation. For example, in 2022 the Inflation Reduction Act, or IRA, included several provisions aimed at lowering prescription drug costs. The public largely supports many of these provisions, including limiting how much drug companies can increase the price of drugs based on annual inflation rates (88%) and allowing the federal government to negotiate with drug companies to get a lower price on medications for people with Medicare (85%).

KFF polling shows the public – across partisans – is also supportive of other policy proposals that have been debated but not been put into law, such as increasing taxes on drug companies that refuse to negotiate the price of their drugs with the government, allowing Americans to buy drugs imported from Canada, making it easier for generic drugs to come to market, and expanding the IRA’s annual out-of-pocket maximum and monthly cap on insulin prices beyond people with Medicare.

Bar chart showing percent who favor specific actions to keep prescription drug costs down.

It is also notable that bipartisan support for the IRA provisions has held since its passage, and majorities across partisan lines support expanding what the law currently does. KFF polling from 2024, during the Biden administration, showed that at least eight in ten (85%) U.S. adults supported authorizing the federal government to negotiate drug prices for people with Medicare as the IRA does. This provision was supported by 90% of Democrats, 87% of independents, and 79% of Republicans.

In 2024, majorities across partisanship also supported expanding two IRA provisions beyond those covered by Medicare. Three in four adults supported a proposal to expand the $35 cap on out-of-pocket costs for insulin beyond those with Medicare, including majorities of Democrats (82%), independents (78%), and Republicans (67%). About two-thirds supported a proposal to expand the $2,000 annual limit on out-of-pocket prescription drug costs beyond those with Medicare, including 78% of Democrats, 69% of independents, and 57% of Republicans.

Bar chart showing shares of total voters, democratic voters, Independent voters, and Republican voters who say they support proposals to expand IRA provisions beyond those with Medicare.

Trump Administration Policy Actions on Prescription Drug Prices, TrumpRx and Direct Purchasing Options

President Trump first pushed to lower prescription drug costs in the U.S. to match prices in other developed nations, during his first term in 2018, an approach that later became formally known as “most-favored-nation” (MFN) pricing. While this was not put into effect during Trump’s first term, KFF polling from 2019 found broad public support for the approach, with about two-thirds (65%) of adults supporting lowering what Medicare pays for some drugs based on amounts in other countries where governments more closely control prices. This includes most Democrats (74%), independents (62%), and Republicans (54%).

Bar chart showing shares of total voters, democratic voters, Independent voters, and Republican voters who say they support proposals to expand IRA provisions beyond those with Medicare.

In the Trump administration’s second term, there have been more efforts to reduce the cost of prescription drugs. Though the details of the deals are confidential and not available to the public, the administration announced several prescription drug pricing deals with drugmakers related to what they charge state Medicaid programs for some of their drugs, and a subsequent deal with a maker of in vitro fertilization (IVF) drugs aimed at lowering the cost of these treatments. As of November 2025, awareness of these deals was limited, with three in ten adults saying they had heard a lot (6%) or some (25%) about them. Later in 2025, the president announced further developments in the MFN pricing, including deals to sell certain products directly to consumers at discounted rates.

In February 2026, amid the Trump administration's focus on lowering prescription drug costs, the administration officially launched TrumpRx, the federal government-run website where people can get discounts to buy prescription drugs directly from some manufacturers or pharmacies, without using their health insurance. As of early March 2026, few U.S. adults overall, including those who take prescription drugs, have heard much about or visited the website.

While few prescription drug users (7%) say they have visited the TrumpRx site to shop for or compare prescription prices in the month following the TrumpRx launch, this rises to about one in six (16%) among those who currently take or have ever taken a GLP-1 medication for weight loss or certain chronic conditions. The TrumpRx website features at least four major GLP-1 medications among its initial 43 listed drugs.

Split bar chart showing shares of adults who say they have heard about TrumpRx and share who say they have visited the TrumpRx website. Results shown by adults who take prescription drugs and GLP-1 use.

Prior to the launch of TrumpRx, drug discounts have been available through third-party platforms and directly from drug manufacturers. About four in ten adults who take prescription drugs say that in the past year, they have used a discount card or coupon to reduce their prescription drug costs (42%) or compared prescription drug prices online to find the lowest cost option (39%). Fewer say they have purchased a lower-cost drug from an online pharmacy without their insurance (15%) or directly from a drug manufacturer’s website (8%). 

Bar chart showing shares of adults who currently take prescription drugs and who say they have not taken their medication as prescribed because of the costs.

U.S. Global Health Country-Level Funding Tracker

Published: Mar 27, 2026

This tracker provides U.S. global health funding data by program area and country. It includes Congressionally appropriated (planned) funding amounts from FY 2006 – FY 2023, as well as obligations and disbursements from FY 2006 – FY 2025 (FY 2025 data are partially reported). Data were obtained from ForeignAssistance.gov (see About This Tracker below for more details). For examples of analyses that can be done using this tracker, please expand the section below.

Tracker

About This Tracker

The U.S. is the largest donor to global health in the world, providing bilateral (direct country-to-country) support for U.S. global health programs in over 75 countries in FY 2023 (through appropriated/planned funding), with additional countries reached through U.S. regional efforts and U.S. contributions to multilateral organizations. This tracker provides historical data on bilateral U.S. government funding for global health by country, region, and income-level. It presents data on country-specific global health funding channeled through the Department of State (State) and U.S. Agency for International Development (USAID); these agencies account for approximately 85% of all U.S. funding for global health. Funding channeled through other agencies – the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and Department of Defense (DoD) – is not included, as these data are not available at the country-level. Funding directed to “regional” or “worldwide” programs, which may reach additional countries, is also not included. See our companion resource, KFF U.S. Global Health Budget Tracker, to view data on U.S. funding for global health overall, including funding channeled through these other agencies. Data in this tracker present three transaction types:

  1. Appropriated: funding amounts based on Congressional appropriations for a given fiscal year which may be obligated and disbursed over a multi-year period;
  2. Obligations: binding agreements that will result in disbursements (or outlays), immediately or in the future, and
  3. Disbursements: actual paid amounts (an outlay of funds) to a recipient in a given year.

These amounts will be updated as new data become available. Queried data can be downloaded using the button within the interactive, and the full data can be downloaded here. For questions related to this resource, or for inquiries on further analyses on U.S. global health funding, please contact globalhealthbudget@kff.org.

Sources

KFF analysis of data from the U.S. Foreign Assistance Dashboard, U.S. State Department regional classifications, and World Bank income classifications.

One or Two Health Systems Controlled the Entire Market for Inpatient Hospital Care in Nearly Half of Metropolitan Areas in 2024

Published: Mar 27, 2026

Editorial Note: This brief updates a previous analysis with more recent data, an evaluation of increases in concentration over time, and minor adjustments to the Methods.

National health spending totaled $5.3 trillion in 2024—18% of gross domestic product (GDP)—and is projected to grow faster than GDP through 2033, contributing to higher costs for families, employers, states, and the federal government. As policymakers consider a variety of strategies to make health care more affordable, they have been increasingly attentive to the effects of consolidation in health care markets and the potential implications for cost and quality of care. Hospital consolidation has been a subject of particular focus in part because spending on hospital care is the largest source of spending on health. Hospital care has also contributed more than other categories to the growth in national health spending over time, including from 2022 to 2024, when it accounted for 40% of spending growth. Consolidation may allow providers to operate more efficiently and help struggling providers keep their doors open in underserved areas, but it often reduces competition. A substantial body of evidence has found that consolidation can contribute to higher prices, with unclear effects on quality.

This analysis examines the competitiveness of markets for hospital care, based on RAND Hospital Data—a cleaned and processed version of cost reports from Medicare-certified hospitals—and American Hospital Association (AHA) survey data. The analysis examines competition among independent hospitals and health systems, referring to both as “health systems” throughout for brevity. Competition is measured in three ways: the share of metropolitan statistical areas (MSAs) controlled by a small number of health systems, the level of market concentration in MSAs based on the Herfindahl-Hirschman Index (HHI), and the share of hospitals affiliated with health systems over time. Using hospital data from 2024 (the most recent year available), this analysis focuses on general short-term or general medical and surgical hospitals depending on the dataset and excludes federal hospitals (see Methods for more details).

Key Takeaways

  • One or two health systems controlled the entire market for inpatient hospital care in nearly half (47%) of metropolitan areas in 2024.
  • In more than four of five metropolitan areas (83%), one or two health systems controlled more than 75 percent of the market.
  • Nearly all (97% of) metropolitan areas had highly concentrated markets for inpatient hospital care when applying HHI thresholds from antitrust guidelines to MSAs.
  • Most hospital markets in metropolitan areas (80%) became less competitive from 2015 to 2024 or were controlled by one health system over that entire period.

One or Two Health Systems Controlled the Entire Market for Inpatient Hospital Care in Nearly Half (47%) of Metropolitan Areas in 2024

Nearly one in five (19%) metropolitan statistical areas (MSAs) were controlled by a single health system, and more than one in four (27%) markets were controlled by two systems in 2024 (see Figure 1). In more than four of five metropolitan areas (83%), one or two health systems controlled more than 75 percent of the market. These markets all met the definition of highly concentrated markets based on thresholds in current antitrust guidelines (see below). One health system controlled at least half of the market in about three out of four MSAs (76%) and at least a quarter of the market in nearly every MSA (98%).

One or Two Health Systems Controlled the Entire Market for Inpatient Hospital Care in Nearly Half of Metropolitan Areas in 2024 (Small multiple donut chart)

The number of health systems in a given MSA tends to increase with the population of the region. For example, in 79% of MSAs with a population of less than 200,000, one or two health systems controlled the entire market for inpatient hospital care in 2024, as in the Muncie, IN; Napa, CA; and Amherst Town-Northampton, MA MSAs (Figure 2). MSAs with one or two health systems account for nearly half (47%) of all MSAs but 12% of the U.S. population living in metropolitan areas.

Conversely, virtually all (54 of 55) MSAs with a population of at least one million people had at least four health systems, as in the MSAs encompassing Detroit, Miami, and Phoenix. MSAs with four or more health systems accounted for 35% of all MSAs but 79% of the U.S. population living in metropolitan areas.

However, in fourteen of these relatively large MSAs with four or more health systems, the two largest health systems controlled at least 75% of the market, and in 44 of these areas, they controlled at least 50% of the market. For example, in the MSA encompassing Austin, TX, with 2.6 million residents, two systems (HCA Healthcare and Ascension Healthcare) controlled 89% of the inpatient hospital care market, though Austin is home to more than four health systems. The metropolitan area encompassing Portland, OR, with 2.5 million residents and more than four health systems, is a less concentrated market than Austin’s, but the two largest systems (Legacy Health and Providence) still control a combined 62% of the market. (See Methods for discussion about MSAs as geographic hospital markets).

Hospital Market Competitiveness Varied Across US Metropolitan Areas in 2024 (Symbol map)

Nearly All (97% of) Metropolitan Areas Had Highly Concentrated Markets for Inpatient Hospital Care in 2024 Based on Thresholds Used in Current Antitrust Guidelines

Another way to assess market competitiveness is to evaluate a measure of concentration known as the Herfindahl-Hirschman Index (HHI), which is based on the number of participants in a market and their respective shares. The measure runs from 0 (perfectly competitive) to 10,000 (monopoly market). Based on current merger guidelines from the Federal Trade Commission (FTC) and Department of Justice (DOJ), markets can be grouped into three categories: not concentrated (HHI < 1,000), moderately concentrated (1,000 – 1,800), and highly concentrated (HHI > 1,800). This analysis calculates HHIs for MSAs and groups these regions accordingly, though there are other ways of defining the boundaries of hospital markets (see Methods).

Nearly all (97% of) MSAs had highly concentrated markets for inpatient hospital care in 2024 based on thresholds used in current merger guidelines (Figure 3). These guidelines reflect updates in 2023 that lowered the HHI thresholds for moderately concentrated and highly concentrated markets. Based on the thresholds used in prior guidelines, a large majority but somewhat smaller share (93%) of MSAs were highly concentrated markets for inpatient hospital care in 2024, closer to an estimate from an earlier study (90%) that used data from 2016.

As was the case when looking at counts of health systems in MSAs, larger metropolitan areas tended to be less concentrated and more competitive than less populated metropolitan areas, although this was not always the case. All 10 MSAs that were identified as either not concentrated or moderately concentrated had more than one million residents, such as the MSAs encompassing Cincinnati, Los Angeles, and Miami. However, 45 MSAs with more than one million residents—including the MSAs encompassing Houston, Denver, and Atlanta—had highly concentrated hospital markets. Overall, 72% of people living in metropolitan areas lived in highly concentrated hospital markets.

Nearly All (97% of) Metropolitan Areas Had Highly Concentrated Markets for Inpatient Hospital Care in 2024 Based on Thresholds Used in Current Antitrust Guidelines (Donut Chart)

The Share of Hospitals Affiliated With Health Systems Increased From 56% in 2010 to 69% in 2024, With the Share Growing in Both Rural and Urban Areas

More than two thirds of hospitals (69%) are now part of a larger system, an increase from 56% in 2010 (Figure 4). A smaller share of rural than urban hospitals were part of a health system in 2024 (53% versus 80%), though shares have increased over time for both rural and urban regions: from 43% in 2010 to 53% in 2024 among rural hospitals and from 66% in 2010 to 80% in 2024 among urban hospitals.

Most system-affiliated hospitals in 2024 (52%) were part of a system with at least 15 hospitals, and 19% were in a system with at least 50 hospitals. Systems with at least 100 hospitals accounted for 10% of system-affiliated hospitals.

Hospitals joining larger systems may not always reduce local market competition, for example, if an independent hospital is acquired by a larger system that does not own facilities in the same market. However, mergers between hospitals that operate in different geographic markets for patient care—also known as “cross-market” mergers—may nonetheless lead to higher prices in some cases.

The Share of Hospitals Affiliated With Health Systems Increased From 56% in 2010 to 69% in 2024, With the Share Growing in Both Rural and Urban Areas (Line chart)

Most Hospital Markets in Metropolitan Areas (80%) Became More Concentrated From 2015 to 2024 or Were Controlled by One Health System Over That Entire Period

Four out of five metropolitan areas (80%) experienced an increase in hospital market concentration between 2015 and 2024 (Figure 5) or were controlled by a single hospital or health system for the duration. About two thirds of MSAs (65%) saw an increase in market concentration over this period, as measured by HHI, and the share of MSAs that were highly concentrated increased by two percentage points, from 95% to 97%. Fifteen percent of metropolitan areas were controlled by a single health system in both 2015 and 2024, meaning that concentration could not increase further in these markets. Concentration declined in only 20% of markets. In some cases, increases or decreases in concentration were very small.

Most Hospital Markets in Metropolitan Areas (80%) Became More Concentrated From 2015 to 2024 or Were Controlled by One Health System Over That Entire Period (Donut Chart)

The trend toward greater concentration was widespread across metropolitan areas of different sizes and regions. Among the 65% of MSAs that experienced increased concentration, the average HHI increased from 4,545 to 5,273, a 728 point increase. In markets that are not already controlled by one hospital or health system, market concentration may rise as a result of continued consolidation through mergers and acquisitions (Figure 4), shifts in hospital stays towards larger hospitals and health systems and away from smaller competitors, or hospital closures that reduce the number of competitors in a given market.

This work was supported in part by Arnold Ventures. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.

Methods

Analyses of market shares and HHI (e.g., every figure except for Figure 4) were based in part on RAND Hospital Data. RAND Hospital Data are a cleaned and processed version of annual cost reports that Medicare-certified hospitals are required to submit to the federal government. Although limited to Medicare-certified hospitals, in 2024, the analysis of RAND data included the vast majority (98%) of non-federal general medical and surgical hospitals in US metropolitan areas included in the analysis of system affiliation based on the AHA Annual Survey Database (see below). Cost reports were assigned to years based on the end of the reporting period and were scaled up or down to reflect a 365-day period, as necessary. In cases where a hospital had multiple cost reports assigned to the same analysis year, the cost report covering the longer reporting period was retained. When cost reports were longer than 365 days and fully spanned a calendar year (such as one beginning 1/1/2022 and ending 7/31/2023), the cost report was assigned to both the year spanned in full (2022) and the year in which it ended (2023).

Analyses of market shares and HHI were restricted to non-federal, general short-term hospitals as identified in the RAND Hospital Data. Some general short-term hospitals in the analysis were identified as other hospital types, such as surgical hospitals, in the AHA data (6% of those that could be matched), though these represented a small share of discharges (1%). Market shares were calculated as the share of inpatient discharges in an MSA that occurred within a given health system or independent hospital. One percent of hospitals that met the other sample restrictions had missing values for inpatient discharges and were excluded. Hospitals were grouped into health systems, as applicable, based primarily on the hospital’s system affiliation in the AHA Annual Survey Database. A previous version of this analysis relied on the AHRQ Compendium of US Health Systems, but that file has not been updated to include 2024 information.

For 2024 analyses, in the small number of cases where a cost report could not be matched to the AHA Annual Survey database (2% of observations), the 2023 AHRQ Compendium was used to identify the hospital's corresponding AHA system identifier, where available. Twelve hospitals could not be matched to AHA or AHRQ records, of which 7 were manually assigned system affiliations based on internet searches. System affiliations for 40 hospitals (2% of the sample) were updated using the 2023 AHRQ Compendium when confirmed by internet searches in cases where: (1) the Compendium identified at least two hospitals in an MSA as being part of a Compendium health system that did not correspond to an AHA system and (2) at least one of those hospitals was identified as independent in the AHA data. In 3 instances (covering 11 hospitals), two AHA systems were combined into one when indicated by the AHRQ Compendium and confirmed through internet searches.

Analyses of changes in system affiliation and market structure over time (Figures 4 and 5) relied only on AHA system identifiers. When cost reports did not match to AHA data in the Figure 5 analysis, those hospitals were treated as independent.

MSAs reflect 2023 geographic definitions from the Census Bureau delineated based on data from the 2020 decennial census. HHIs were calculated as the sum of squared market shares for all health systems in a given MSA (e.g., an MSA divided evenly between two systems would have an HHI of 502 + 502 = 5,000). MSA population estimates for 2024 were obtained from the Census Bureau.

MSAs were used as a proxy for hospital markets, which is one approach used by other studies summarizing hospital market competition across the country. There are other ways of defining markets that would yield different results when calculating the level of competition. For example, one report also evaluated MSAs but focused on where residents received their care, including at hospitals outside of a given MSA. As another example, some have defined markets based on a radius around the hospital defined by distance or estimated travel time. More precise market definitions, such as those used to define competition in antitrust cases, were not feasible. This study did not exclude MSAs with populations of at least three million as some others have done, because the analysis sought to describe competition across all metropolitan areas.

The analysis of the share of hospitals affiliated with systems was based on the AHA Annual Survey Database alone. This analysis was restricted to nonfederal, general medical and surgical hospitals. Urban hospitals were defined as those operating in a metropolitan area, while rural hospitals were defined as those operating in nonmetropolitan areas. Metropolitan and nonmetropolitan designations were identified using Urban Influence Codes (UIC) data.

LGBT People Experience Widespread Concerns and Challenges When it Comes to Health Care Affordability

Published: Mar 26, 2026

Introduction

Costs associated with health care and other household expenses weigh heavily on LGBT adults and health care affordability is poised to be a significant issue for all voters as we approach the 2026 midterm elections. This data note highlights the health care affordability challenges facing LGBT adults, a growing population that faces health related disparities, including related to both mental and physical health. At the same time, LGBT adults are a lower income group compared to non-LGBT adults. Findings from KFF Health Tracking Polls show that LGBT adults face more widespread concerns with affording basic necessities, including health care, compared to non-LGBT adults.

Findings

LGBT people, like the public overall, worry about the economy, with eight in ten (83%) LGBT adults saying their cost of living has increased in the past year, including more than half (58%) who say it has increased “a lot.” These are similar to the concerns among non-LGBT adults, 82% of whom say their cost of living has increased, including half who say it has increased “a lot”. Very small shares of both groups say their cost of living has “decreased” (4% of LGBT and 5% of non-LGBT adults). About one in ten LGBT and non-LGBT adults say their living expenses have remained stable over the past year (13% and 12%, respectively).

About Eight in Ten LGBT Adults Say Their Cost of Living Has Increased in the Past Year, Similar to Non-LGBT Adults (Stacked Bars)

Large majorities of both LGBT adults and non-LGBT adults worry about being able to afford health care for themselves and their family, with health care topping the list of economic worries for non-LGBT adults. However, LGBT adults have broader and more pronounced concerns related to affording basic necessities across multiple categories. Three-quarters of LGBT adults (76%) say they worry about paying for health care, including the cost of health insurance and out-of-pocket costs for things like office visits and prescription drugs. This ranks similarly to their financial worries related to other household expenses like food and groceries (also 76%), rent or mortgage (74%), and monthly utilities (71%). In each case, these concerns are more widespread than those of non-LGBT adults, likely reflecting LGBT adults’ lower incomes. Cost-concerns related to gas and transportation were somewhat lower for LGBT adults (67%) compared to other household expenses but still outpaced worries among non-LGBT adults (51%). However, the survey was conducted prior to the recent rise in gas prices in the wake of the Iran war.

Large Shares of LGBT Adults Worry About Affording Basic Necessities, Including Health Care, With Concerns More Common Than Among Non-LGBT Adults (Bar Chart)

When asked specifically about prescription medication costs, nearly two-thirds of LGBT adults (64%) say that they are worried about being able to afford prescription drug costs for themselves and their family, similar to the share of non-LGBT adults (58%). However, LGBT adults are more likely to say they are “very worried” about these costs than non-LGBT adults (36% v. 20%).

Nearly Two-thirds of LGBT Adults Worry About Affording Prescription Medications (Stacked Bars)

In addition to reporting worries related to health care affordability, LGBT adults commonly report facing difficulty with these expenses in their day-to-day lives. Four in ten LGBT adults (43%) report problems paying for health care, and a similar share (39%) say they had problems affording prescription drugs in the past year. In both cases LGBT adults report experiencing these difficulties at higher rates than non-LGBT adults.

LGBT Adults Commonly Face Difficulty Paying for Health Care and Prescription Drugs (Bar Chart)

VOLUME 43

New KFF Tracking Poll on Health Information and Trust Finds One in Three Adults Have Used AI Chatbots for Health Advice


Highlights

KFF’s latest Tracking Poll on Health Information and Trust finds that one-third of the public report using AI chatbots for health information and advice in the past year, similar to the share who have relied on social media for health. One in five adults who use AI for health cite difficulties accessing or affording health care as reasons they turned to these chatbots, including larger shares of younger and lower income users. These findings, as well as data from dozens of past KFF polls, are also available on KFF’s Health Information and Trust Polling dashboard.

And a federal judge suspended, for now, the appointments of thirteen members of the Advisory Committee on Immunization Practices (ACIP), the federal committee responsible for recommending vaccines to Americans, halting a scheduled meeting and staying recent changes to the childhood vaccine schedule. The ruling comes as KFF polling finds that fewer than half of U.S. adults express confidence in federal agencies to make recommendations about the childhood vaccine schedule, with more adults saying recent changes will have a negative rather than positive impact on children’s health.


KFF Poll Finds One in Three Adults Have Used AI for Health Information and Advice in the Past Year, With Younger Users More Likely to Cite Difficulty Accessing or Affording Health Care as a Reason They Turned to AI

Amid the AI technology boom, KFF’s latest Tracking Poll on Health Information and Trust finds that one-third (32%) of the public says they used AI for health information and advice in the past year – rivaling the share who have sought health information from social media in the past year (29%), but less common than seeking health advice from doctors (80%) or internet search engines (68%), which may themselves include AI-generated summaries.

The share of adults who report using AI for health information in the past year includes three in ten (29%) who say they sought information or advice about their physical health and about one in six (16%) who sought information or advice about their mental health. Compared to older adults, larger shares of adults under age 30 (who are more likely to use AI in the first place) say they turned to AI for information or advice related to their physical health (36%) or mental health (28%). When it comes to use of AI for mental health advice, Black adults and Hispanic adults, as well as those who are uninsured, are more likely to say they have used the technology.

Split bar chart showing percent who say they have sought information or advice about physical or mental health from artificial intelligence tools in the past year. Results shown by total adults, age, race and ethnicity, and insurance coverage.

Public trust in AI for health information is relatively low, particularly for those who have not used these tools or chatbots for health advice. About eight in ten adults who have not used AI for health or mental health information say they trust these tools “not too much” or “not at all” to provide reliable information about health or mental health. Conversely, majorities of adults who have used AI for health or mental health information say they trust these chatbots “a great deal” or “a fair amount” to provide reliable information on health (69%) or mental health (62%), respectively. At the same time, there is some skepticism among users, with three in ten (31%) who use AI for physical health saying they don’t trust AI for reliable information on health, and nearly four in ten (38%) who use AI for mental health saying they don’t trust these tools to provide reliable mental health information.

Split bar chart showing trust in AI tools to provide reliable information about health and mental health respectively. Results shown by total adults and by use of AI for different types of health information.

What We're Watching

Court Ruling on Vaccine Schedule May Add to Confusion as Trust in Federal Recommendations Declines

A federal judge has blocked recent changes to the federal childhood vaccine schedule and suspended, for now, the appointments of some members of the advisory committee responsible for making vaccine recommendations. The lawsuit, brought by the American Academy of Pediatrics (AAP) and other medical organizations, argued that changes to the Advisory Committee on Immunization Practices’ (ACIP’s) membership and decision-making process undermined the committee’s credibility and departed from established standards. The AAP also alleged that the committee relied on what it called “spurious evidence” to make its recommendations and suggested that committee members and speakers made inaccurate or misleading claims prior to votes. The ruling does not assess the merits of the changes to vaccine recommendations, instead focusing on whether federal procedures for appointing committee members and developing recommendations were followed. The administration has indicated it is weighing its legal options, including a potential appeal, meaning the dispute could continue, but AAP’s president has framed the decision as a win for science that would bring clarity to vaccine recommendations. A KFF Quick Take provides additional detail on the ruling and what may come next.

For parents, patients, and providers, the ruling and ongoing dispute may deepen existing confusion about which vaccine guidance to trust. KFF’s January Tracking Poll on Health Information and Trust found that among adults who had heard about the recent changes to the childhood vaccine schedule (51% of all adults), twice as many said the changes would have a negative impact on children’s health (54%) as said they would have a positive impact (26%). As of early March, 29 states and Washington, D.C. had announced they would no longer fully follow the new CDC childhood vaccine schedule, creating a patchwork of vaccine guidance that varies by state.

What To Watch Out For: How will the ruling, future actions by the administration, and the growing divide between guidance from federal agencies and professional medical organizations affect vaccine-related narratives and public trust?

Polling Insights: KFF’s January Tracking Poll on Health Information and Trust, conducted shortly after changes to the federal vaccine schedule recommendations were announced, found that fewer than half of adults are confident in federal health agencies to make recommendations about childhood vaccines. Overall, just under half (44%) of adults said they have at least “some confidence” in federal health agencies to make recommendations about childhood vaccine schedules, including about half (51%) of Democrats and fewer than half of independents (45%) and Republicans (40%).

Stacked bar chart showing percent who say they have a lot, some, a little, or no confidence at all in the federal government health agencies to make recommendations about childhood vaccine schedules. Results shown by total adults, party ID, and support for the Make America Healthy Again movement.

Beyond making recommendations for childhood vaccines, fewer than half of the public expressed confidence in these agencies to ensure vaccine safety and effectiveness (46%), make decisions based on science (38%), or act independently (34%). Across partisanship, fewer than half of Democrats, independents, and Republicans are confident in these agencies to act independently or make decisions based on science.

Public Trust Higher in CDC, NIH, FDA Scientists Than Federal Health Agency Leadership

Two-thirds of Americans (67%) are confident that career scientists at federal health agencies, including the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and Food and Drug Administration (FDA), are providing the public with trustworthy health information, compared to 43% who said the same of the leaders of those agencies, according to a new poll from the Annenberg Public Policy Center. This new poll gives additional context to KFF polling that has found declining public trust in agencies like the CDC and FDA since the beginning of the COVID-19 pandemic.

What To Watch Out For: The gap between trust in career scientists and trust in agency leadership may take on added significance as changes are made to the federal health workforce. The NIH, for example, has lost more than 20% of its workforce since the start of the Trump administration, according to federal data reported by KFF Health News. As thousands of career scientists leave, federal agencies may face additional challenges in maintaining capacity and public confidence.


More From KFF

About The Health Information and Trust Initiative: the Health Information and Trust Initiative is a KFF program aimed at tracking health misinformation in the U.S., analyzing its impact on the American people, and mobilizing media to address the problem. Our goal is to be of service to everyone working on health misinformation, strengthen efforts to counter misinformation, and build trust. 


View all KFF Monitors

The Monitor is a report from KFF’s Health Information and Trust initiative that focuses on recent developments in health information. It’s free and published twice a month.

Sign up to receive KFF Monitor
email updates


Support for the Health Information and Trust initiative is provided by the Robert Wood Johnson Foundation (RWJF). The views expressed do not necessarily reflect the views of RWJF and KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities. The data shared in the Monitor is sourced through media monitoring research conducted by KFF.

Deaths and Health Care Issues in ICE Detention Centers Under the Second Trump Administration

Published: Mar 25, 2026

Introduction

As of March 18, 2026, Immigration and Customs Enforcement (ICE) reported that 46 people died while in their custody or detention facilities since the start of the second Trump administration in January 2025. The number of deaths of people in detention during 2025 exceeded the highest seen in over two decades, and deaths in 2026 are on track to meet or exceed that number. President Trump implemented immigration policy changes focused on increasing interior enforcement efforts to support mass deportation, which increased the number of immigrants detained by ICE to over 68,000 as of February 7, 2026, an increase of over 70% from the 39,000 immigrants held in detention at the end of the Biden administration in December 2024.

ICE is required to maintain certain basic health and safety standards in all detention facilities, which include an initial medical and mental health screening as well as comprehensive health services that include diagnoses and treatments, transfers to off-site medical care when necessary, and access to 24-hour emergency care. However, detention facilities have a history of inadequate compliance with health and safety standards, insufficient health care, shortages in health care staffing, and limited oversight, which may create health risks for those detained. The increased number of people in detention facilities and overcrowding of facilities may further increase health risks, particularly for communicable diseases like measles and people with complex medical conditions. This brief provides an overview of deaths in ICE custody and detention centers under the Trump administration based on KFF analysis of ICE detainee death reporting and news releases and reviews recent reports of health care issues in detention centers.

Deaths in ICE Custody and Detention

The number of deaths occurring among people in ICE custody or detention increased from 11 in 2024 and less than ten in earlier years to 33 in 2025 after the Trump administration took office (Figure 1). ICE is required to publish a news release with relevant details regarding custody deaths within two days, while full reports regarding custody deaths are published within 90 days of occurrence that may contain more details from investigations into the deaths. Six of the deaths that occurred between January 1, 2025 and March 18, 2026 were among people with no reported criminality or pending criminal charges. A total of 36 deaths occurred among people who spent three or fewer months in ICE detention, including those ICE transferred to a hospital for additional medical care. Thirty-eight (38) deaths occurred among people younger than age 65, and 21 were among those under age 45 (Figure 2). Twenty-two (22) deaths were among people from Mexico and Central America, while ten were among people from Asia.

Total Annual Deaths Under ICE Custody or Detention, January 2021-March 2026 (Column Chart)
Deaths in ICE Custody or Detention by Age, January 1, 2025-March 18, 2026 (Pie Chart)

A total of 32 deaths among people in ICE custody or detention between January 2025 and March 2026 were among people with existing medical conditions who appeared to experience worsening health complications contributing to their death, while the remaining share were reported as due to suicide or other causes (Figure 3). While ICE does not always report an official cause of death as determined by a medical examiner, they report the details of initial health screenings and medical history. The causes of death due to health complications and the initial severity of health conditions varied. For example, ICE detained a 68-year-old adult with reported mild blood pressure issues who experienced steadily worsening symptoms over the course of two months that led to his hospitalization and death. In contrast, a 55-year-old adult with severe physical and mental health issues was transferred one day after his arrest to a hospital, where he stayed until his death. ICE reported the remaining deaths as suicide (9) and other causes (5), such as a fatal traffic collision during arrest. ICE reporting may differ from independent assessments of deaths. For example, the El Paso County Medical Examiner’s Office in Texas ruled a death in January 2026 to be a homicide due to the actions of enforcement officers, while ICE reported it as a suicide.

ICE Reported Causes of Death for Deaths Occurring Under ICE Custody or Detention, January 1, 2025-March 18, 2026 (Pie Chart)

Reported Health Care Issues

The Trump administration’s mass deportation efforts led to a significant increase in immigrants held in detention centers, which can lead to overcrowding if deportations do not keep up with the pace of arrests as well as challenges to accessing health care due to limited capacity and resources. Moreover, ICE payments to contractors providing medical care in detention facilities lapsed after the Department of Veterans Affairs terminated a longstanding agreement to process medical reimbursement claims in October 2025, which may impact certain health care services as the new claims system may not be active until April 2026. Overcrowding as well as limited capacity and resources may also increase the risk of the spread of communicable diseases, such as measles. For example, media reports indicate that recent measles outbreaks in Arizona and Texas detention facilities may have been the result of overcrowding and delays in providing vaccinations. ICE also terminated the contract with a private company that operated the Texas detention facility in March 2026 according to a media report indicating that, despite having no prior experience, the company was selected to build and operate the largest ICE facility and that there were reports of inadequate health care.

Reports since January 2025 suggest ICE may not be maintaining health and safety standards for immigrants held in detention centers. ICE is responsible for oversight and management of health care in detention facilities, but it has a history of inadequate compliance with detention standards and provides little to no publicly available data on health care use, quality, and outcomes. A 2025 report based on an investigation launched by Democratic Senator Jon Ossoff of Georgia documented instances of lack of access to prescribed medications, mistreatment of pregnant women, malnutrition and dehydration, unsanitary conditions, sleep deprivation, and abuse in detention facilities. A report based on interviews with people held at an Arizona detention facility between July 2024 to November 2025 conducted by a nonprofit organization serving detainees found instances of medical and mental health care lapses, such as several month delays in necessary specialty treatment and people with serious mental illnesses never seeing a mental health provider. Other media reports indicate instances of lost medical treatments and prescriptions during transfers between detention facilities.

There have also been recent reports of health care issues for children and pregnant people held in detention under the Trump administration. A media report on a Texas facility, where over half of detainees during the first nine months of the Trump administration were children, identified problematic health care issues, including inadequate staffing of pediatricians and child psychologists. Additionally, although ICE policy limits the detention of pregnant, postpartum, and nursing individuals to “very limited circumstances,” ICE data shared in response to an inquiry from Democratic Senator Patty Murray of Washington showing that 121 were detained as of February 16, 2026. This stands in contrast to when most of these groups were released on parole according to the most recent publicly available ICE report on these groups from the first half of fiscal year 2024. A media report and interviews conducted by legal organizations in 2025 with pregnant, postpartum, and nursing individuals in ICE detention identified gaps in prenatal and postnatal care. Another media report based on interviews with pregnant individuals held in ICE detention between 2025 and 2026 identified reports of excessive bodily restraints, inadequate nutrition and prenatal care, delayed emergency care, and an instance where ICE attempted to deport an individual in a late-term and high-risk pregnancy.

Several legal challenges related to poor health care conditions and limited oversight have been brought against ICE, some of which resulted in court rulings requiring ICE to implement changes. In February 2026, a judge ruled that ICE was required to improve conditions in California detention facilities due to poor conditions, including by ensuring adequate health care staffing, access to medical specialists, and providing timely care and medications. ICE faces pending lawsuits alleging that they delayed providing cancer care medication for an extended period of time during transit between facilities between August and October 2025 and that they provided inadequate medical care in Illinois in October 2025. In March 2026, local officials in California filed lawsuit to gain access to ICE facilities and conduct public health inspections after being denied access, and Maryland filed a lawsuit to obtain records detailing conditions at an immigration detention facility in Baltimore after investigations revealed multiple issues, including denial of medical care. These lawsuits to increase oversight followed a previous court order for ICE to restore unannounced congressional oversight visits to DHS facilities. A court order also required the Trump administration to restore DHS oversight offices that investigated issues of neglect and mistreatment in the ICE facilities. Despite reversing their decision to close the offices, the administration faces additional legal challenges due to low staffing in the offices that may reduce their ability to investigate ICE facility health care issues. The outcomes of court orders may change due to appeals by the Trump administration.

Poll Finding

KFF Tracking Poll on Health Information and Trust: Use of AI For Health Information and Advice

Published: Mar 25, 2026

Findings

Key Takeaways

  • With the recent explosion of consumer artificial intelligence (AI) tools and chatbots, KFF’s latest Tracking Poll on Health Information and Trust finds about a third (32%) of adults are turning to AI for health information and advice. This includes about three in ten (29%) who say they’ve used AI tools in the past year for information or advice about their physical health, and one in six (16%) who’ve used them for mental health information or advice. AI use is on par with the share who say they turn to social media for health information, but lags behind the shares saying they’ve sought health information from health care providers and internet search engines (where they may be encountering AI generated results, even if they are not looking for them).
  • Larger shares of younger adults, uninsured adults, Black adults, and Hispanic adults are turning to AI chatbots for mental health advice. About three in ten (28%) of those ages 18 to 29 say they’ve used AI for information about their mental health or emotional wellbeing in the past year, compared to about one in five (18%) adults ages 30 to 49 and about one in ten of those ages 50 and older. Uninsured adults are more likely than insured adults to say they’ve relied on AI for mental health advice (30% v. 14%), as are Black (21%) and Hispanic (19%) adults compared to White adults (12%).
  • Among the top reasons given for turning to AI for health information, most users (65%) say a desire for quick and immediate advice was a “major reason,” for doing so, while many also cite wanting to look up information before seeing a provider (41%) or feeling more comfortable looking up health questions privately (36%). Difficulty accessing or affording health care is also driving some to rely on AI for health information, particularly younger and lower-income users. About one in five AI health users cite not having a health care provider or not being able to get an appointment as a major reason they used AI for health advice, rising to four in ten (38%) among users ages 18 to 29. Another one in five users say difficulty affording health care was a major reason they relied on AI for health advice, rising to three in ten (29%) among users ages 18 to 29 and one-third (32%) among those with annual incomes below $40,000.
  • A majority (77%) of the public says they are concerned about the privacy of personal medical information provided to AI tools, including similar majorities across age groups and those who use AI for health information. Despite these privacy concerns, about four in ten (41%) of those who have used AI for physical or mental health (amounting to 13% of all adults), say they’ve uploaded personal medical information into an AI tool or chatbot.

AI Use for Health Information and Advice

KFF’s latest Tracking Poll on Health Information and Trust finds that use of and exposure to artificial intelligence has become omnipresent in most Americans’ lives, and some are turning to these tools for health information and advice at a time when several technology companies have announced the launch of health-specific chatbots.

Overall, four in ten (39%) adults say they actively use AI tools at least several times a week, while eight in ten say they come across AI-generated content at least several times a week, even if they are not actively looking for it.

About a third (32%) of the public reports turning to AI chatbots for physical or mental health advice – rivaling social media as a health information source, but less common than reliance on health care providers or internet search engines. The share using AI for health advice includes about three in ten (29%) who say they’ve sought information or advice about their physical health from an AI tool or chatbot in the past year, as well as one in six (16%) who say they’ve sought information or advice about their mental health from AI tools in the past year. Comparably, large shares of the public report seeking physical or mental health information and advice from a health care professional (80%) or an internet search engine (68%) in the past year. Given that many search engines now provide AI-generated summaries of search results, much of the public may be getting AI-generated health information, even if they are not looking for it.

Split bar chart showing percent who have sought information or advice about their physical or mental health from specific sources in the past year.

Use of AI tools for health information is more common among younger adults (as is AI use overall), particularly when it comes to mental health. Over one-third (36%) of adults ages 18 to 29 report using AI tools or chatbots for information or advice related to their physical health in the past year and about three in ten (28%) say the same about their mental health or emotional wellbeing. Those ages 18 to 29 are at least three times as likely as adults ages 50 and older to report using AI for mental health advice (28% v. 8%).

Larger shares of uninsured adults, Black adults, and Hispanic adults report turning to AI for mental health advice in the past year compared to fewer insured adults and White adults, respectively. Use of AI for physical health advice does not differ by race and ethnicity or health insurance status. Notably, race and ethnicity, age, and health insurance coverage are interrelated, as younger adults and Hispanic adults are more likely to be uninsured.

Split bar chart showing percent who say they have sought information or advice about physical or mental health from artificial intelligence tools in the past year. Results shown by total adults, age, race and ethnicity, and insurance coverage.

People report using AI for health information in various ways, but most commonly to look for general information about health conditions or symptoms. About a quarter (27%) of adults used AI for physical health questions in the past year and say they did so to look up symptoms or general information about health conditions. About one in five adults say they used AI to get explanations of medical tests, lab results, or diagnoses (19%) or understand and compare treatment options (19%), while about one in six (16%) say they used AI in the past year to get help deciding whether to see a doctor or seek medical care.

Bar chart showing percent who say they have used artificial intelligence tools for information and advice about their physical health in the past year, and whether they have used it for specific reasons.

Overall, about one in ten adults say they used AI for information related to their mental health or emotional wellbeing in the past year and did so to look up symptoms or get general information about a mental health condition (11%), get advice or coping skills for mental health issues (11%), understand and compare treatment options (10%), or to talk through personal mental health concerns like a conversation with a companion (9%). Seven percent of adults say they turned to AI to get help deciding whether to seek professional mental health care.

Bar chart showing percent who have used AI for mental health information in the past year, and whether they have used it for specific reasons.

About six in ten (58%) adults who used AI for physical health advice in the past year say they later followed up with a doctor or health care provider after consulting an AI tool, while about four in ten (42%) of those who used AI for mental health say they followed up with a mental health professional.

Mirrored bar chart showing percent who say they did or did not follow up with a doctor after using AI for information related to their physical or mental health.

Overall, larger shares of younger adults compared with older adults report consulting AI for health information and then not following up with a doctor. About one in five (21%) adults ages 18 to 29 (who are more likely to have used AI for health in the first place) say they turned to AI for physical health advice in the past year and then did not follow up with a doctor – about twice the share of those ages 30 and older who report doing so. Similarly, about one in six (16%) adults ages 18 to 29 say they used AI for mental health advice in the past year and did not follow up with a doctor or mental health professional, more than twice the share of adults ages 50 and older who say the same.

Split bar chart showing percent who say they used AI for their physical or mental health, respectively, and did not follow up with a doctor. Results shown by total adults and age.

Reasons for Using AI for Health Information and Advice

Among those who have used AI tools or chatbots for physical or mental health information in the past year (32% of all adults), most users (65%) cite wanting quick or immediate information or support as a “major reason” for doing so. Many users cite other “major” reasons, including that they wanted to look up information before deciding whether to see a provider (41%), they felt more comfortable looking up health-related topics privately (36%), or they received medical test results before being able to discuss them with provider (28%).

Some users say they turned to AI due to difficulty accessing or affording health care, with about one in five saying a “major reason” they used AI for health was because they could not afford the cost of seeing a provider (19%) or they don’t have a regular health care provider or could not get an appointment (18%).

While about one in five AI users (18%) say a “major reason” they used AI for health was because they felt the information was as reliable as what a health care provider would tell them, most users (65%) say this was at least a “minor reason” for using AI.

Stacked bar chart showing percent who say specific reasons were "major" or "minor" reasons for using AI tools for health information.

While wanting quick or immediate information is the top reason for using AI across groups, younger adults and lower-income adults are more likely to cite difficulty accessing or affording health care as their reason for relying on AI for health information. Among those who have used AI for health information in the past year, adults under age 30 are six times as likely as users 50 and older to cite not having a regular health care provider or being unable to get an appointment (38% v. 6%) and more than twice as likely to cite not being able to afford the cost of a provider (29% v. 12%) as major reasons for turning to AI for health advice. Among adults with annual household incomes less than $40,000 who have used AI for health, one-third (32%) cite not being able to afford a health care provider as a “major reason” for using AI, while one in four cite not having a regular health care provider.

Notably, younger adults are more likely than older adults to not have health insurance coverage and to have lower annual household incomes.

Split bar chart showing percent who say specific reasons were "major" reasons for using AI for health information. Results shown by total adults, age, and household income.

Trust and Satisfaction in AI for Health Information and Advice

Among adults who used AI for physical or mental health advice in the past year, large majorities say they were at least “somewhat satisfied” with the quality of the responses they received related to their physical health (92%) or mental health (85%), though relatively small shares say they were “very satisfied” (19% and 27%, respectively).

Stacked bar chart showing satisfaction with the quality of response received from AI tools when used for information related to physical health and mental health.

At least six in ten adults who have used AI for advice related to their physical health or mental health say they trust AI tools “a great deal” or “a fair amount” to provide reliable information about health (69%) or mental health (62%), respectively.

On the other hand, trust in AI tools for health information is relatively low among the public overall, and especially among those who have not used these tools. Trust in AI for health information drops to about one in five (18%) among adults who have not used AI for physical health advice, while trust in AI for mental health information drops to about one in six (16%) among those who have not used AI for mental health advice.

Split bar chart showing trust in AI tools to provide reliable information about health and mental health respectively. Results shown by total adults and by use of AI for different types of health information.

Privacy Concerns and Uploading Personal Medical Data to AI

Recently, several major technology companies have launched dedicated AI health products, promoting them as personalized health tools where users can connect and upload their medical records. Although most adults, including AI users, have concerns about privacy of personal medical information provided to AI chatbots, many who use AI for health still report uploading personal medical information to an AI tool or chatbot.

Among adults who have used AI for physical or mental health information in the past year (32% of all adults), about four in ten (41%) say they have uploaded personal medical information like test results or doctor’s notes. Overall, this means 13% of all adults say they have entered personal medical information into an AI tool to get an explanation or advice related to their health, rising to about one in five adults ages 18 to 29 (19%).

Bar chart showing percent who say they have ever entered personal medical information into an AI tool. Results shown by total adults, adults who have used AI for health, and age.

Although AI chatbots are commonly trained on user conversations, some AI companies have said that conversations with their health-specific AI tools won’t be used for training. Still, a large majority of the public, including most AI users, say they have concerns about the privacy of personal health information uploaded to AI chatbots. About three in four (77%) adults say they are either “very” or “somewhat” concerned about the privacy of personal medical information provided to AI tools, including similar shares across age groups.

Even among adults who report having entered personal medical information into an AI tool, most (65%) say they are concerned about privacy of this information, though just a quarter say they are “very concerned.”

Stacked bar chart showing concern about the privacy of personal medical information provided to AI tools. Results shown by total adults, age, and whether they have used AI for health information.

Methodology

This KFF Health Tracking Poll/KFF Tracking Poll on Health Information and Trust was designed and analyzed by public opinion researchers at KFF. The survey was conducted February 24 – March 2, 2026, online and by telephone among a nationally representative sample of 1,343 U.S. adults in English (n=1,268) and in Spanish (n=75). The sample includes 1,019 adults (n=62 in Spanish) reached through the SSRS Opinion Panel either online (n=995) or over the phone (n=24). The SSRS Opinion Panel is a nationally representative probability-based panel where panel members are recruited randomly in one of two ways: (a) Through invitations mailed to respondents randomly sampled from an Address-Based Sample (ABS) provided by Marketing Systems Groups (MSG) through the U.S. Postal Service’s Computerized Delivery Sequence (CDS); (b) from a dual-frame random digit dial (RDD) sample provided by MSG. For the online panel component, invitations were sent to panel members by email followed by up to three reminder emails.

Another 324 (n=13 in Spanish) adults were reached through random digit dial telephone sample of prepaid cell phone numbers obtained through MSG. Phone numbers used for the prepaid cell phone component were randomly generated from a cell phone sampling frame with disproportionate stratification aimed at reaching Hispanic and non-Hispanic Black respondents. Stratification was based on incidence of the race/ethnicity groups within each frame. Among this prepaid cell phone component, 142 were interviewed by phone and 182 were invited to the web survey via short message service (SMS).

Respondents in the prepaid cell phone sample who were interviewed by phone received a $15 incentive via a check received by mail or an electronic gift card incentive. Respondents in the prepaid cell phone sample reached via SMS received a $10 electronic gift card incentive. SSRS Opinion Panel respondents received a $5 electronic gift card incentive (some harder-to-reach groups received a $10 electronic gift card). In order to ensure data quality, cases were removed if they failed two or more quality checks: (1) attention check questions in the online version of the questionnaire, (2) had over 30% item non-response, or (3) had a length less than one quarter of the mean length by mode. Based on this criterion, 1 case was removed.

The combined cell phone and panel samples were weighted to match the sample’s demographics to the national U.S. adult population using data from the Census Bureau’s 2024 Current Population Survey (CPS), September 2023 Volunteering and Civic Life Supplement data from the CPS, and the 2025 KFF Benchmarking Survey with ABS and prepaid cell phone samples. The demographic variables included in weighting for the general population sample are gender, age, education, race/ethnicity, region, civic engagement, frequency of internet use and political party identification. The weights account for differences in the probability of selection for each sample type (prepaid cell phone and panel). This includes adjustment for the sample design and geographic stratification of the cell phone sample, within household probability of selection, and the design of the panel-recruitment procedure.

The margin of sampling error including the design effect for the full sample is plus or minus 3 percentage points. Numbers of respondents and margins of sampling error for key subgroups are shown in the table below. For results based on other subgroups, the margin of sampling error may be higher. Sample sizes and margins of sampling error for other subgroups are available on request. Sampling error is only one of many potential sources of error and there may be other unmeasured error in this or any other public opinion poll. KFF public opinion and survey research is a charter member of the Transparency Initiative of the American Association for Public Opinion Research.

GroupN (unweighted)M.O.S.E.
Total1,343± 3 percentage points
   
Party ID  
Democrats449± 6 percentage points
Independents449± 6 percentage points
Republicans373± 6 percentage points
   
MAGA Republicans/Republican leaning independents334± 6 percentage points
   
Used AI for health information or advice in the past year458± 6 percentage points
Used for physical health information407± 6 percentage points
Used for mental health information234± 8 percentage points
News Release

Poll: 1 in 3 Adults Are Turning to AI Chatbots for Health Information, Equaling the Share Who Use Social Media for Health

1 in 5 Who Use AI for Health Cite Affordability and Access Concerns as Major Reasons, Including Larger Shares of Young and Lower Income People

Published: Mar 25, 2026

About a third (32%) of adults nationally say they have turned to artificial intelligence (AI) chatbots in the past year for health information, a new KFF Tracking Poll on Health Information and Trust finds. Most who turned to AI for health information say they were in search of quick and immediate advice, though challenges affording and accessing health care also play a role, particularly for younger adults.

The share using AI for health advice includes about 3 in 10 (29%) who have sought information related to their physical health and about 1 in 6 (16%) who have sought information related to their mental health. People are about as likely to use AI as social media to find health information.

As with AI use generally, younger adults are more likely than older adults to rely on AI for health information, particularly for mental health.

For example, adults under age 30 are about three times as likely as adults ages 50 and older to use AI for mental health information (28% vs. 8%). Uninsured adults are also more likely than those with insurance to do so (30% vs. 14%), as are Black and Hispanic adults compared to White adults.

When asked why they consulted AI for health information, about two-thirds (65%) of users say that a major reason was to get quick or immediate information or support. Substantial shares also cite wanting to look up information before deciding whether to see a provider (41%) or feeling more comfortable looking up information privately (36%).

Challenges affording and accessing health care are also driving some to rely on AI, particularly for younger adults and those with lower incomes. About 1 in 5 say that not being able to afford the cost of seeing a health professional (19%) or not having a regular doctor or not being able to get an appointment (18%) was a major reason for turning to AI.

Larger shares of young users (under age 30) cite barriers to affording (29%) or accessing (38%) health care as a major reason they relied on AI for health advice. Similarly, users with low incomes (less than $40,000 annually) are more likely to cite both health care costs (32%) and access (25%) as major factors for using AI.

Many people who consult AI for health information say they did not follow up with a doctor or other health professional afterward, including most (58%) who asked about mental health, and 42% who asked about physical health. Younger adults are more likely than older adults to have used AI for health advice and then not followed up with a doctor.

Many AI Users Upload Personal Health Information Despite Privacy Concerns

Among those who use AI for health information, 41% say that they have uploaded personal medical information like test results or doctors’ notes into an AI tool or chatbot to get personalized explanations or advice related to their health. This means 13% of the public has uploaded personal medical information to an AI chatbot for this purpose.

Among the public at large, about three-quarters (77%) say that they are concerned about the privacy of personal medical information provided to AI tools, including most (65%) of those who have shared personal medical information with AI.

Designed and analyzed by public opinion researchers at KFF, this survey was conducted February 24-March 2, 2026, online and by telephone among a nationally representative sample of 1,343 U.S. adults in English and in Spanish. The margin of sampling error is plus or minus 3 percentage points for the full sample. For results based on other subgroups, the margin of sampling error may be higher.